Jacques-Camarena Omar, González-Ortiz Manuel, Martínez-Abundis Esperanza, López-Madrueño J F Pariz, Medina-Santillán Roberto
Medical Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, West National Medical Center, Mexican Institute of Social Security, Guadalajara, Mexico.
Ann Nutr Metab. 2008;53(3-4):195-8. doi: 10.1159/000175844. Epub 2008 Nov 22.
BACKGROUND/AIM: Impaired glucose tolerance (IGT) is considered a risk factor for developing type 2 diabetes mellitus (T2DM) and is associated with insulin resistance. Vanadium seems to block protein tyrosine phosphatase with the consequent increment in insulin sensitivity (INS) in T2DM patients, but this effect has not been studied in IGT patients. The aim of this study was to evaluate the effect of vanadium on INS in IGT patients.
A randomized, double-blind, placebo-controlled clinical trial was carried out in 14 overweight/obese patients with IGT. Intervention consisted of vanadyl sulfate (VS, 50 mg p.o. twice daily) or placebo for 4 weeks. Before and after the intervention, a metabolic profile was performed and INS was assessed using the euglycemic-hyperinsulinemic clamp technique. Mann-Whitney U and Wilcoxon rank tests were used for statistical analyses.
There were no significant differences in basal characteristics between groups. VS did not affect INS [2.7+/-0.8 vs. 2.9+/-0.9 mg/(kg/min), p=0.735] but increased triglyceride levels (1.35+/-0.61 vs. 1.70+/-0.46 mmol/l, p=0.018).
VS administration in IGT patients increased triglyceride concentrations without changes in INS.
背景/目的:糖耐量受损(IGT)被认为是发生2型糖尿病(T2DM)的一个危险因素,且与胰岛素抵抗相关。钒似乎可阻断蛋白酪氨酸磷酸酶,从而使T2DM患者的胰岛素敏感性(INS)增加,但尚未在IGT患者中研究这种效应。本研究的目的是评估钒对IGT患者INS的影响。
对14例超重/肥胖的IGT患者进行了一项随机、双盲、安慰剂对照的临床试验。干预措施为硫酸氧钒(VS,口服50 mg,每日两次)或安慰剂,持续4周。干预前后进行了代谢指标检测,并采用正常血糖-高胰岛素钳夹技术评估INS。采用Mann-Whitney U检验和Wilcoxon秩和检验进行统计分析。
两组间基础特征无显著差异。VS对INS无影响[2.7±0.8 vs. 2.9±0.9 mg/(kg/min),p = 0.735],但甘油三酯水平升高(1.35±0.61 vs. 1.70±0.46 mmol/l,p = 0.018)。
IGT患者服用VS可使甘油三酯浓度升高,但INS无变化。